Estrogen Receptor-Alpha, Breast Cancer Patients And Tamoxifen Response

Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen receptor (ER)-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), according to a brief communication published online November 25 in the Journal of the National Cancer Institute. Approximately 50% of breast carcinomas are resistant to tamoxifen.

source : www.medicalnewstoday.com

Related News:

• Kidney Cancer Drug Shows Promising Results
• Launch Of Ipsen’s Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Prostate Cancer
• Barker Hypothesis Strengthened By Ancient Tooth Remains
• Scientists At Rice University Discover That ‘Nanobubbles’ Kill Cancer
• AM: Opioid Gains Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Launch Of Ipsen’s Decapeptyl 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Advanced Or Metastatic Hormone-Dependent Prostate Cancer
• Green Tea Extracts Halt Growth of Prostate Cancer Tumors
• AM: Opioid Shows Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Recordati : Silodosin Approved By The European Commission For The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia
• EMEA Gives Official Scientific Advice On Clinical Phase IIb Efficacy Study Of Inecalcitol In Hormone-refractory Prostate Cancer

Details :
Submited at Friday, November 27th, 2009 at 7:00 am on Endocrinology by admin
Comment RSS 2.0 - leave a comment - trackback